Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843399 · ClinicalTrials.gov registry record
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 15,498
- Enrollment target
NCT02843399: Completed study, sponsored by AstraZeneca.
NCT02843399 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 15,498 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02843399 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 15,498 participants
- Enrollment target
Study Summary
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
Primary Outcome
Compare diabetes-related healthcare utilization and costs in patients initiating EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,498 participants |
| Start Date | 2016-08-15 |
| Est. Completion | 2016-12-15 |
What the finished NCT02843399 record still lists
NCT02843399 is an observational study that tracks outcomes without assigning an intervention. Its 15,498 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02843399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02843399 about?
NCT02843399 is a clinical study titled "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy". Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
What is the current status of trial NCT02843399?
This trial is currently completed. The enrollment target is 15,498 participants. The study started on 2016-08-15. Estimated completion is 2016-12-15.
Who is sponsoring clinical trial NCT02843399?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05447806 · 15,732 participants · NA
Diabetes Clinical Decision Support
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI